These Definitive Additional Materials are
being filed to amend and supplement certain information that was provided in Transgenomic Inc.’s Definitive Proxy Statement,
dated May 12, 2017. Other than the amended and supplemented information included in these Definitive Additional Materials, no other
changes have been made to the Definitive Proxy Statement, and it continues to be in full force and effect as originally filed with
the Securities and Exchange Commission on May 12, 2017. Transgenomic continues to seek the vote of Transgenomic stockholders for
all proposals to be voted on at the special meeting of stockholders. Capitalized terms used but not otherwise defined in these
Definitive Additional Materials have the meanings ascribed to them in the Definitive Proxy Statement. These Definitive Proxy Materials
should be read together with the Definitive Proxy Statement.
SUPPLEMENT TO PROXY STATEMENT
May 25, 2017
These Definitive Additional Materials amend
and supplement the Definitive Proxy Statement dated May 12, 2017 (the “Definitive Proxy Statement”), initially mailed
to stockholders on or about May 15, 2017, by Transgenomic, Inc., a Delaware corporation (“Transgenomic), for a meeting of
stockholders of Transgenomic to be held at Troutman Sanders LLP’s offices located at 1001 Haxall Point, Richmond, Virginia
23219 on June 5, 2017 at 10:00 a.m. Eastern time. The purpose of the special meeting is to consider and vote upon, among other
items, proposals relating to the issuance of shares of New Precipio common stock and New Precipio preferred stock in connection
with the Merger Agreement and related transactions, including the conversion of certain secured indebtedness of Transgenomic and
a private placement with certain investors. Transgenomic expects the merger and related transactions to close in June 2017.
If any stockholders have not already
submitted a proxy for use at the meeting of stockholders, they are urged to do so promptly. No action in connection with these
Definitive Additional Materials is required by any stockholder who has previously delivered a proxy and who does not wish to revoke
or change that proxy.
Your vote is very important. We cannot complete
the merger, the conversion of secured debt and the private placement without the approval of the issuance of New Precipio common
stock, including the shares that may be issued upon future conversion of New Precipio preferred stock. This approval requires the
affirmative vote of the holders of a majority of the common stock and Series A-1 Convertible Preferred Stock, voting together as
a single class (with each one share of Series A-1 Convertible Preferred Stock being entitled to 0.93 votes), present in person
or represented by proxy at the special meeting at which a quorum is present. Even if you plan to attend the special meeting, we
recommend that you submit your proxy before the special meeting so that your vote will be counted if you later decide not to attend
the meeting. You can also vote your shares via the Internet or by telephone as provided in the instructions set forth on the enclosed
proxy card. If you hold your shares in ‘‘street name’’ through a broker, you should follow the procedures
provided by your broker.
For additional questions about the merger,
the conversion of secured debt, private placement and other proposals, assistance in submitting proxies or voting your shares,
or to request additional copies of the Definitive Proxy Statement, please contact our proxy solicitor at:
Innisfree M&A Incorporated
501 Madison Avenue, 20th Floor
New York, New York 10022
Stockholders may call toll free: (888) 750-5834
(toll-free from the U.S. and Canada)
Banks and brokers may call collect: (212)
750-5833.
The information contained herein speaks only as of May 25, 2017,
unless the information specifically indicates that another date applies.
SUPPLEMENTAL DISCLOSURES TO DEFINITIVE
PROXY STATEMENT
This supplemental information should be read in conjunction
with the Definitive Proxy Statement, which should be read in its entirety. Transgenomic believes that no further disclosure is
required to supplement the Definitive Proxy Statement under applicable laws; however to avoid the risk that lawsuits may delay
or otherwise adversely affect the consummation of the proposed merger and to minimize the expense of defending such action, Transgenomic
wishes to voluntarily make supplemental disclosures related to the proposed merger, which are set forth below, in response to certain
allegations. Nothing in these supplemental disclosures shall be deemed an admission of the legal necessity or materiality under
applicable laws of any of the disclosures set forth herein. Defined terms used but not defined herein have the meanings set forth
in the Definitive Proxy Statement.
THE TRANSACTION
Background of the Transaction
The following disclosure supplements and restates the
third full paragraph on page 35 of the Definitive Proxy Statement
.
On April 4, 2016, a representative of Craig-Hallum
reported to senior management of Transgenomic that Craig-Hallum had contacted 88 strategic investors, 24 of whom did not respond,
35 expressed no interest,
28 executed non-disclosure agreements, received the confidential information
memorandum and had access to the data room but decided not to move forward and one made an offer. Of the 28 executed non-disclosure
agreements, 14 had standard standstill provisions, 14 had no standstill provisions and none had a “don’t ask, don’t
waive” provision
.
With respect to the one offer received by Transgenomic, the strategic
investor proposed to issue shares of common stock with a value of approximately $2.6 million in an asset purchase to purchase
all of Transgenomic’s intellectual property and related assets.
Opinion of Craig-Hallum Capital Group LLC – Comparable
Public Company Analysis
The disclosure under the sub-heading “
Comparable
Public Company Analysis of Transgenomic
” beginning on page 47 of the Definitive Proxy Statement is supplemented by inserting
the following table directly after the table titled “Transgenomic Comparable Group” on page 48 of the Definitive Proxy
Statement.
|
|
Transgenomic
Comparable Companies
|
|
|
|
LTM
Multiples
|
|
|
2017E
Multiples
|
|
|
2018E
Multiples
|
|
|
|
Revenue
|
|
|
EBITDA
|
|
|
Revenue
|
|
|
EBITDA
|
|
|
Revenue
|
|
|
EBITDA
|
|
Bio-Rad
Laboratories, Inc.
|
|
|
2.2
|
x
|
|
|
15.2
|
x
|
|
|
2.2
|
x
|
|
|
15.6
|
x
|
|
|
2.1
|
x
|
|
|
NA
|
|
Cancer Genetics, Inc.
|
|
|
1.3
|
x
|
|
|
NM
|
|
|
|
0.7
|
x
|
|
|
NM
|
|
|
|
0.4
|
x
|
|
|
NA
|
|
Enzo Biochem Inc.
|
|
|
2.1
|
x
|
|
|
NM
|
|
|
|
NA
|
|
|
|
NA
|
|
|
|
NA
|
|
|
|
NA
|
|
Fluidigm Corporation
|
|
|
2.8
|
x
|
|
|
NM
|
|
|
|
2.2
|
x
|
|
|
NM
|
|
|
|
1.9
|
x
|
|
|
NM
|
|
OpGen, Inc.
|
|
|
6.7
|
x
|
|
|
NM
|
|
|
|
4.9
|
x
|
|
|
NA
|
|
|
|
NA
|
|
|
|
NA
|
|
Qiagen NV
|
|
|
5.8
|
x
|
|
|
18.6
|
x
|
|
|
5.2
|
x
|
|
|
16.2
|
x
|
|
|
4.9
|
x
|
|
|
15.3
|
x
|
Note that certain EBITDA multiples were not meaningful
(NM) because the EBITDA value was negative for the associated comparable company.
The disclosure under the sub-heading “
Comparable
Public Company Analysis of Precipio
” beginning on page 49 of the Definitive Proxy Statement is supplemented by inserting
the following table directly after the table titled “Precipio Comparable Group” on page 49 of the Definitive Proxy
Statement.
|
|
Precipio
Comparable Companies
|
|
|
|
LTM
Multiples
|
|
|
2017E
Multiples
|
|
|
2018E
Multiples
|
|
|
|
Revenue
|
|
|
EBITDA
|
|
|
Revenue
|
|
|
EBITDA
|
|
|
Revenue
|
|
|
EBITDA
|
|
Cancer Genetics,
Inc.
|
|
|
1.3
|
x
|
|
|
NM
|
|
|
|
0.7
|
x
|
|
|
NM
|
|
|
|
0.4
|
x
|
|
|
NA
|
|
Enzo Biochem Inc.
|
|
|
2.1
|
x
|
|
|
NM
|
|
|
|
NA
|
|
|
|
NA
|
|
|
|
NA
|
|
|
|
NA
|
|
Genomic Health Inc.
|
|
|
3.1
|
x
|
|
|
NM
|
|
|
|
2.7
|
x
|
|
|
60.6
|
x
|
|
|
2.3
|
x
|
|
|
30.9
|
x
|
Neogenomics Inc.
|
|
|
4.3
|
x
|
|
|
27.4
|
x
|
|
|
2.7
|
x
|
|
|
14.3
|
x
|
|
|
2.3
|
x
|
|
|
11.1
|
x
|
OpGen, Inc.
|
|
|
6.7
|
x
|
|
|
NM
|
|
|
|
4.9
|
x
|
|
|
NA
|
|
|
|
NA
|
|
|
|
NA
|
|
Note that certain EBITDA multiples were not meaningful (NM)
because the EBITDA value was negative for the associated comparable company.
The following disclosure supplements and restates the
second full paragraph under the sub-heading “Comparable M&A Transaction Analysis” on page 50 of the Definitive
Proxy Statement.
The group was comprised of the following
transactions and is referred to in this proxy statement as the “Precedent Transaction Group:”
Buyer
|
|
Target
|
|
Implied EV to
LTM Revenue
|
Myriad Genetics, Inc.
|
|
AssureRx Health, Inc.
|
|
6.8x
|
Luminex Corporation
|
|
Nanosphere, Inc.
|
|
4.0x
|
NeoGenomics Laboratories, Inc.
|
|
Clarient, Inc.
|
|
2.2x
|
OpGen, Inc.
|
|
AdvanDx, Inc.
|
|
0.3x
|
Opko Health, Inc.
|
|
Bio-Reference Laboratories Inc.
|
|
1.6x
|
Neogenomics Inc.
|
|
Path Logic, Inc.
|
|
0.6x
|
Myriad Genetics, Inc.
|
|
Crescendo Bioscience, Inc.
|
|
9.5x
|
bioMérieux S.A.
|
|
Argene SA
|
|
4.3x
|
Luminex Corporation
|
|
EraGen Biosciences, Inc.
|
|
4.3x
|
GE Healthcare Limited
|
|
Clarient, Inc.
|
|
4.6x
|
WHERE YOU CAN
FIND ADDITIONAL INFORMATION
Transgenomic is subject to the informational
requirements of the Exchange Act. Accordingly, Transgenomic files annual, quarterly and current reports, proxy statements and
other information with the SEC. Transgenomic also furnishes to its stockholders annual reports, which include financial statements
audited by independent certified public accountants and other
reports which the law requires to be sent to stockholders. The public may read and copy any reports, proxy statements or other
information that Transgenomic files at the SEC’s public reference room at 100 F Street, N.E., Room 1580, Washington,
D.C. 20549. The public may obtain information at the public
reference room by calling the SEC at 1-800-SEC-0330. Transgenomic’s SEC filings are also available to the public from commercial
document retrieval services and at the web site maintained by the SEC at www.sec.gov. You may obtain a copy of any of these documents,
at no cost, by writing or telephoning at the following address:
Transgenomic, Inc.
12325 Emmet Street
Omaha, Nebraska
Attention: Corporate Secretary
(402)-452-5400
If you have any questions about the Definitive Proxy Statement
or these definitive additional materials, the stockholders meeting, or if you would like additional copies of the Definitive Proxy
Statement or these definitive additional materials, please contact our proxy solicitor at:
Innisfree M&A Incorporated
501 Madison Avenue, 20th Floor
New York, New York 10022
Stockholders may call toll free: (888) 750-5834
(toll-free from the U.S. and Canada)
Banks and brokers may call collect: (212)
750-5833
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING
STATEMENTS
These Definitive Additional Materials together
with the Definitive Proxy Statement contain “forward-looking statements.” Forward-looking statements relate to expectations,
beliefs, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical
facts or that necessarily depend upon future events. In some cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “could,” “would,” “expect,” “plan,”
“anticipate,” “believe,” “estimate,” “project,” “predict,” “potential,”
and similar expressions. Without limiting the generality of the preceding sentence, statements contained in the sections ‘‘Summary,’’
‘‘The Transaction — Transgenomic’s Reasons for the Transaction,’’ and ‘‘The Transaction
— Opinion of Craig-Hallum Capital Group LLC’’ include forward-looking statements. Forward looking statements
contained in these Definitive Additional Materials and the Definitive Proxy Statement include projections of earnings, revenues,
synergies, accretion or other financial items; any statements of the plans, strategies and objectives of management for future
operations, including the execution of integration plans and the future management of New Precipio; approvals relating to, and
the closing of, the merger with Precipio and the private placement; any statements regarding future economic conditions or performance;
and statements of belief and any statement of assumptions underlying any of the foregoing.
The forward-looking statements contained
in these Definitive Additional Materials and the Definitive Proxy Statement reflect Transgenomic’s current views about future
events, are based on assumptions, and are subject to known and unknown risks and uncertainties. Many important factors could cause
actual results or achievements to differ materially from any future results or achievements expressed in or implied by Transgenomic’s
forward-looking statements, including the factors listed below. Many of the factors that will determine future events or achievements
are beyond Transgenomic’s ability to control or predict. The following factors include, among others: the ability of the
parties to satisfy the conditions precedent and consummate the proposed merger, the timing of consummation of the proposed merger,
the ability of the parties to secure any required stockholder or other approvals in a timely manner or on the terms desired or
anticipated, the ability to achieve anticipated benefits, risks related to disruption of management’s attention due to the
pending merger, operating results and businesses generally, the outcome of any legal proceedings related to the proposed merger
and the general risks associated with the respective businesses of Transgenomic and Precipio, including the general volatility
of the capital markets, terms and deployment of capital, volatility of the Transgenomic share price, changes in the biotechnology
industry, interest rates or the general economy, underperformance of Transgenomic’s and Precipio’s assets and investments
and decreased ability to raise funds, the degree and nature of Transgenomic’s and Precipio’s competition and other
risks as described in Transgenomic’s reports filed with the SEC.
The forward-looking statements contained in these Definitive
Additional Materials and the Definitive Proxy Statement reflect Transgenomic’s views and assumptions only as of the date
of the Definitive Additional Materials and the Definitive Proxy Statement, respectively. You should not place undue reliance on
forward-looking statements. Except as required by law, Transgenomic assumes no responsibility for updating any forward-looking
statements.
Transgenomic’s actual results, performance or achievements
could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause
or contribute to such differences are discussed in the section entitled ‘‘Risk Factors’’ beginning on
page 20 of the Definitive Proxy Statement and the section entitled “Risk Factors” included in Transgenomic’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and risk factors detailed in Transgenomic’s most
recent quarterly report on Form 10-Q. Transgenomic qualifies all of its forward-looking statements by these cautionary statements.